Regeneron Pharmaceuticals (REGN)EVP Commercial sold ~$970K

~$970K

Approx. value · 1,131 sh @ $857.39

12K

Holds after · shares reported

Traded

Sep 3, 2026

Filed

Sep 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 27, 2026CongressDisclosed purchase of REGN — reported range $1,001 - $15,000
2. Jul 2, 2026InsiderDirector sold ~$130K of REGN shares in the open market
3. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
4. Jul 16, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: Cheatham v. Regeneron Pharmaceuticals, Inc.
5. Jul 28, 2026FDARecall: Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pha…
6. Jul 30, 2026Company filing · Form 8-K · ResultsReported its results
7. Aug 10, 2026Insider · 2 peopleInsiders: 2 sales (~$960K)
8. Aug 19, 2026FDAFDA drug approval: Pasatru
9. Sep 2, 2026Insider · 2 peopleInsiders: 2 sales (~$1.4M)
10. Sep 3, 2026 · this disclosureInsiderOfficer sold ~$970K of REGN shares in the open market

What came next

1. Sep 23, 2026Court · District Court, S.D. New YorkSecurities lawsuit filed: Hopkinson v. Regeneron Pharmaceuticals, Inc.
2. Sep 24, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 24, 2026 (the “ Grant Date ”), the Compensation Committee (the “ Compensation Committee ”) of the Board of Directors (the “ Board ”) of Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) granted, upon the approval of the independent, non-employee members of the Board, a one-time award of performance share units (together, the “ 2026 PSUs ”) under the Second Amended and Restated…”
3. Oct 1, 2026Company filing · Form 8-K · Material agreement, ResultsSigned an important agreement, and reported its results (and 1 more item)
4. Oct 1, 2026Government · Federal Register noticeAdvisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Regeneron Pharmaceuticals

For Regeneron Pharmaceuticals, OQRO holds 8 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 31 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its REGN page.

Other recent filings by Marion Mccourt, EVP Commercial

• SEC Form 4 at Regeneron Pharmaceuticals (REGN)Sep 3, 2026
• SEC Form 4 at Regeneron Pharmaceuticals (REGN)Nov 5, 2024
• SEC Form 4 at Regeneron Pharmaceuticals (REGN)Oct 3, 2024

The full history of Marion Mccourt, EVP Commercial is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Regeneron Pharmaceuticals

• SEC Form 144Sep 3, 2026
• SEC Form 4Sep 3, 2026
• SEC Form 4Sep 3, 2026
• SEC Form 144Sep 2, 2026
• SEC Form 144Sep 2, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its REGN page.